SINO BIOPHARM (01177.HK) announced that the National Medical Products Administration of the People’s Republic of China has approved the Passing of the Consistency of Quality and Efficacy Evaluation for Generic Drugs for 'Imatinib Mesylate Capsules', an oncology medicine of Chia Tai-Tianqing Pharmaceutical Group Co. Ltd., a subsidiary of the company.

Imatinib Mesylate is a Bcr-Abl tyrosine kinase inhibitor for the treatment of the patients with chronic myeloid leukemia (CML) in the blast phase, accelerated phase or chronic phase at which α-interferon therapy fails.